Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 213,805	$ 1,908
Accounts receivable	164,407	0
Prepaid expenses and other assets	18,694	0
Loan receivable from Emergence Global Enterprises Inc. - related party	0	17,901
Total current assets	396,906	19,809
Other assets
Operating lease right-of-use assets	150,323	0
Other receivable	0	113,999
Note receivable - CEN Biotech Ukraine LLC - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,299,328	1,179,328
Property and equipment, net	103,825	0
Intangible assets, net	5,278,867	4,956,147
Goodwill	1,127,857	0
Total assets	8,401,965	6,314,142
Current liabilities
Accounts payable	283,694	190,716
Accounts payable – related parties	61,651	8,347
Loans payable	1,986,670	527,379
Loans payable – related parties	2,701,452	1,363,354
Convertible notes payable	749,526	6,652,448
Convertible notes payable- related parties	1,036,434	2,558,681
Accrued interest	1,323,520	1,125,034
Accrued interest – related parties	1,804,448	1,615,880
Operating lease liabilities	94,439	22,895
Accrued expenses	829,266	641,023
Total current liabilities	10,871,100	14,705,757
Operating lease liabilities, less current portion	224,336	142,102
Patent acquisition liability	354,900	1,380,000
Convertible notes, less current portion	0	78,000
CEBA loan payable	31,396	0
Total liabilities	11,481,732	16,305,859
Shareholders’ deficit
Common stock; unlimited authorized shares; 47,786,013 and 27,557,363 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. No par value.	0	0
Additional paid-in capital	40,860,279	17,068,810
Accumulated deficit	(43,895,667)	(27,060,527)
Accumulated other comprehensive loss	(44,379)	0
Total shareholders’ deficit	(3,079,767)	(9,991,717)
Total liabilities and shareholders’ deficit	$ 8,401,965	$ 6,314,142